Zydus Lifesciences share price will remain in focus on October 3 after the company received tentative approval from the ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

Zydus Lifesciences received an Establishment Inspection Report (EIR) from the USFDA for its Ahmedabad facility. Shares rose ...

Last week, brokerage firm UBS Securities also initiated a 'sell' call on Aurobindo Pharma, assigning it a price target of Rs ...

Aurobindo Pharma receives USFDA approval for Cephalexin tablets, expected to launch in Q3FY25 with CGT designation.

The inspection, which took place between September 23 and September 27, 2024, concluded with 4 observations from the ...

Biocon shares fell 2% to Rs 361.5 after the USFDA issued four observations following an inspection of its Bengaluru API facility. The company will address these within the stipulated time and does not ...

The Hyderabad-based pharmaceutical manufacturing company said the observations are of procedural in nature and will be ...

The inspection closed with 10 observations. The observations are of procedural in nature and will be responded to within the stipulated time.

Aurobindo Pharma gains FDA approval for Cephalexin Tablets, bioequivalent to Keflet, with CGT designation and shared exclusivity.

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide capsules (40 mg), a generic prostate cancer treatment ...